Gastrointestinal Pharmaceuticals: Technologies and Markets

Published - Sep 2009| Analyst - Mary Anne Crandall| Code - PHM046B
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • Overall sales in the gastrointestinal disorder treatment market amounted to $34.2 billionin 2007, and decreased slightly to $31.1 billion in 2009. By 2014, they are projected to reach $32.2 billion, for a 5-year compound annual growth rate (CAGR) of 0.7%.
  • The largest segment of the market, prescription gastrointestinal drugs, was valued at $27.4 billion in 2008; this is expected to decrease to $26,3 billion in 2009, and to reach $27 billion in 2014, for a 5-year CAGR of 0.5%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The objectives of the study are to present a comprehensive look at disorders of the gastrointestinal system and their respective pharmaceutical treatment options. There are two large general categories of gastrointestinal drugs:

  • Prescription
  • Over-the-counter
Markets are further divided according to type of drug. The report is directed to decision-makers within the gastrointestinal market arena.
 
REASONS FOR DOING THE STUDY
 
This BCC study is presented to heighten the awareness of gastrointestinal disorders and identify pharmaceutical preparations and important advancements in the gastrointestinal markets. The study analyzes therapeutics currently on the market as well as potential products and classes of products that are likely to have a significant impact on the future of both the prescription gastrointestinal drug market and the over-the-counter (OTC) gastrointestinal drug market. Manufacturers of gastrointestinal drug products have stepped up the pace of research and development as the engine driving growth in all markets, especially new treatments for Crohn’s disease and irritable bowel syndrome (IBS). Because of the evolving nature of the many areas of gastrointestinal disorders, executives involved in the specific areas within the gastrointestinal drug market must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities within the gastrointestinal marketplace.
 
INTENDED AUDIENCE
 
The information and analyses presented in this report are important assets in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and for consultants to the pharmaceutical and biotechnology industry. The study provides a comprehensive analysis of the current markets for gastrointestinal drugs and, in particular, the market potential of technologies in development.
 
SCOPE OF REPORT
 
This report is designed to be a comprehensive business tool to provide an in-depth look at gastrointestinal disorders. The geographic scope of the report is global with a particular emphasis on the United States. Market data is global. The report provides an overview of the gastrointestinal system; gives a brief explanation of disorders of the gastrointestinal system; cites risk factors, where applicable; cites incidence and mortality; presents current pharmaceutical treatments, market size and market participants in both prescription and OTC arenas; and presents potential treatments in research and development, potential market size, and market participants. This report describes the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future.
 
Within the market for gastrointestinal pharmaceuticals, categories are divided into two general segments:
  • Prescription gastrointestinal pharmaceuticals
  • Over-the-counter gastrointestinal pharmaceuticals
The market is further broken down into the drugs to treat specific disorders within the gastrointestinal system including the following:
  • Gastrointestinal tract disorders
  • Gastrointestinal tract wall disorders
  • Gastrointestinal motility disorders
  • Gastrointestinal malabsorption disorders
  • Gastrointestinal cancers
Each sub segment is addressed in detail, describing disorders and the diseases, identifying current and potential products on the market, and competitors involved in the market.
 
METHODOLOGY AND INFORMATION SOURCES
 
The information and analysis presented in this BCC report are based on extensive firsthand interviews with primary executives, product managers, and clinical specialists in the gastrointestinal pharmaceutical arena. Background information was obtained from various government agencies, business and medical journals, trade magazines, and interviews with doctors and nurses involved in the treatment of gastrointestinal disorders. 
 
Key information from published literature was used to conduct interviews with more than 45 industry participants to validate and obtain expert opinions on current and future trends in the gastrointestinal pharmaceuticals industry. Interviews were the primary basis for development of market size. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections. 
 
All market data pertain to the global market with an emphasis on the U.S. market at the manufacturer’s level. Data are expressed in current U.S. dollars. The base year was 2009. Historical data are provided for 2007 and 2008 and forecast data are provided for 2014. Historical, base year and forecast data are provided for each market segment and sub segment. Market shares are provided for each market segment for the 2009 base year.
 
ANALYST CREDENTIALS
 
Mary Anne Crandall is an expert industry analyst specializing in the pharmaceutical industry for the last 17 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceuticals industry. Ms. Crandall has a BS and MS in psychology and is a retired medical instructor. 
 
BCC ONLINE SERVICES
 
Now you can locate the hard-to-find information you need on the Internet. By directing your browser to BCC’s new “home page,” you will be able to:
  • Examine our complete catalog of Market Research Reports and order directly from BCC
  • Subscribe to any of our more than 20 monthly technology/marketing newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information about any BCC product
  • Take advantage of special offers.
To reach this important new information resource, go to www.bccresearch.com
 
DISCLAIMER
 
This publication provides informative material of a professional nature. It does not constitute managerial, legal, or accounting advice, nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product. This information is intended to be as accurate as possible at the time of publication, but BCC Research assumes no responsibility for any losses or damages that might result because of reliance on this material.
 
Reproduction of any material in this report is strictly forbidden without express permission of the Publisher.
 
To receive a complete catalog of BCC Research studies, please complete the order form at the back of this report or visit our website at www.bccresearch.com.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Sep-2005| Analyst - Mary Anne Crandall| Code - PHM046A

Report Highlights

  • The total U.S. market for gastrointestinal disorder treatments was estimated at $16.1 billion for 2004. Rising at an AAGR (average annual growth rate) of 7.3%, the market is expected to reach $22.8 billion in 2009.
  • The prescription market accounted for the largest percentage of sales with approximately 85%, or $13.7 billion in sales in for 2004. This segment is also rising the fastest, with an AAGR of 7.7%.
  • The OTC market accounts for the remaining 15%, or $2.4 billion. Rising at AAGR of 14%, it will represent only 13% of the market in 2009.
  • At approximately 80%, the largest area of market participation for leading competitors is within the prescription drug segment.
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report